Sexually transmitted infections manifesting as proctitis

Chris A Lamb,1,2 Elizabeth Iris Mary Lamb,1,3 John C Mansfield,4 K Nathan Sankar5

ABSTRACT
There is a rising incidence of several sexually transmitted infections (STIs), many of which can present with proctitis. Causative organisms include Neisseria gonorrhoeae, Chlamydia trachomatis, herpes simplex virus, Treponema pallidum (syphilis), Giardia lamblia (giardiasis) and Entamoeba histolytica (amoebiasis). This paper outlines important clinical discriminators and key investigations to distinguish these organisms from non-infective pathology that include inflammatory bowel disease, solitary rectal ulcer syndrome and Behçet’s syndrome. Management of these infections is described and suggestions are made for successful gastroenterology clinical consultation when an STI is suspected.

INTRODUCTION
Patients presenting to secondary care with symptoms of diarrhoea and rectal bleeding may be found to have features consistent with inflammatory bowel disease (IBD) on endoscopic or radiological investigation. The main differential diagnoses of infectious colitis, ischaemic colitis and non-steroidal anti-inflammatory drug enteropathy are well understood and widely covered in the literature. However, there are several less commonly encountered causes of intestinal inflammation that may not respond to, or be made worse by, immunosuppressant therapy intended for Crohn’s disease or ulcerative colitis. Competency 2.c. of the 2010 Gastroenterology curriculum (box 1) stipulates that UK trainees must have an appreciation of the range of potential aetiologies and the investigative process of differential causes of intestinal inflammation, in order to guide appropriate and successful therapeutic intervention. In the UK and many other western countries there has been a sustained annual increase in the incidence of sexually transmitted infections (STIs) over the past decade.1 Several STIs including gonorrhoea, chlamydia, syphilis and herpes virus can manifest with symptoms and endoscopic features of proctitis. This article outlines these diagnoses and suggests key clinical features or important diagnostic tests that may aid earlier diagnosis and appropriate treatment.

GONORRHOEA
Caused by Neisseria gonorrhoeae, gonorrhoea is transmitted by direct contact of mucosal surfaces, and so proctitis is commonest in men or women participating in receptive anal intercourse, although in women it can occur due to transmucosal spread of infected genital fluid. Symptoms of proctitis are non-discriminatory including lower abdominal pain, diarrhoea, rectal bleeding and tenesmus; however, it may be associated with an anorectal purulent discharge. Diagnostic suspicion should be raised in the presence of urethral discharge and/or pharyngeal infection.2 Anogenital samples should be sent for immediate Gram stain, in which the presence of Gram-negative diplococci are suggestive of a diagnosis with a sensitivity of 90–95%2 (although the specificity of this test may be lower than 60%).3 Nucleic acid amplification tests (NAAT, eg, PCR), although not yet licensed for this anatomical site2 are more sensitive than culture and based on available evidence should be used for diagnosis. In addition, anogenital and pharyngeal swabs in the appropriate transport medium (as advised by the local microbiologist) should also be sent for culture in order to determine antibiotic sensitivities. A high proportion of patients with confirmed gonococcal
infection will also have chlamydia, and so involvement of genitourinary medicine (GUM) specialists and testing for co-infection must be undertaken in confirmed cases.

Treatment of rectal gonorrhoea without available antibiotic sensitivities should be with ceftriaxone 500 mg intramuscularly once, alongside azithromycin 1 g orally once. Gonorrhoea is becoming increasingly resistant to cephalosporins and so repeat testing is advisable following treatment to ensure eradication and to prevent further resistance development. Azithromycin co-treatment with ceftriaxone may improve eradication of gonorrhoea and aims to slow the development of further cephalosporin resistance.

LYMPHOGRANULOMA VENEREUM

There are several serovars of Chlamydia trachomatis. Serovars D–K may lead to superficial rectal mucosal infection (see below); however, serovars L1, L2 and L3 may lead to deeper invasive infection that can affect submucosal tissue and lymphatics, thereby allowing spread to lymph nodes. These invasive serovars are responsible for lymphogranuloma venereum (LGV), also known as lymphogranuloma inguinale, lymphopatia venereum and Durand–Nicolas–Favre’s disease. Previously uncommon in western populations, there have been several outbreaks of this condition in Europe and North America within the past decade. Although LGV affects men and women, the majority of cases occurs in men who have sex with men (MSM). The commonest presentation of the condition is proctitis, usually within several weeks of sexual contact, with symptoms including proctalgia, rectal bleeding and mucopurulent anal discharge. Endoscopic features may mimic IBD proctitis with the additional finding of purulent exudate. Advanced infection may lead to perianal abscess, fistula formation and anorectal stricture. LGV may also exhibit extra-intestinal manifestations including reactive arthritis and hepatitis.

Discriminating factors from IBD include urethral or vaginal mucopurulent discharge, and painful inguinal and femoral lymphadenopathy may be present that can progress to abscess formation. Low-grade pyrexia and rigors may also be discriminating signs.

GUM or infectious disease specialists should be consulted in suspected or confirmed cases of LGV. A diagnosis requires mucosal sampling using anogenital swabs and the detection of L1, L2 or L3 biovar C trachomatis by NAAT and genotyping. Testing for other STIs including HIV (which is particularly associated with LGV), hepatitis B and C, syphilis and gonorrhoea should also be undertaken in confirmed cases. Current European guidance on the management of LGV recommends doxycycline 100 mg twice a day for 21 days first line, or erythromycin 500 mg four times a day for 21 days. Symptoms should abate within 7–14 days. Patients should be advised to abstain from sexual contact until completion of therapy, and sexual partners within the preceding 3 months should be notified and screened for infection. A test of cure should be performed at least 4 weeks following completion of therapy.

CHLAMYDIA

Caused by C trachomatis serovars D–K, transmission of chlamydia is similar to that of N gonorrhoeae. Routine screening using NAAT in GUM clinics detects rectal chlamydia in approximately 10% of MSM and 5% of women. Over 50% of chlamydial infection in MSM is rectal without urethral infection. Approximately 70% of rectal chlamydial infections are asymptomatic; however, mild symptoms of diarrhoea and anal discharge may occur. Occasionally these symptoms can be as severe as LGV or gonorrhoea. Microscopy of anal discharge may show the presence of neutrophils but unlike gonorrhoea, chlamydia cannot be diagnosed by immediate Gram stain. Endoscopy may show a ‘cobblestone’ appearance due to the infiltration of underlying lymphoid follicles.

Although not licensed for extragenital sites, NAAT has been shown to be sensitive and specific and should be requested to diagnose rectal chlamydial infection. APTIMA combo 2 (Hologic Gen-Probe) is a transcription-mediated assay that has the advantage of detecting both N gonorrhoeae and C trachomatis. When requesting NAAT for C trachomatis in the presence of proctitis, genotyping for LGV should be requested as this is not usually carried out on routine specimens.

Rectal chlamydia is best treated with doxycycline 100 mg twice a day for 1 week. (In cases of proctitis in which LGV is a possibility a 3-week course of doxycycline can be started pending the test results. If LGV is excluded, the treatment can be stopped after 1 week.) An alternative is azithromycin 1 g as a single dose but up to 20% treatment failure has been observed and therefore a test of cure with repeat NAAT after 6 weeks is recommended.

HERPES SIMPLEX VIRUS

Caused by either herpes simplex virus (HSV) type 1 or type 2, primary herpes simplex infection may be asymptomatic, but 40% of men and 70% of women will develop systemic features that include malaise, headaches and muscle pain. HSV ascends peripheral sensory nerves then lies dormant in sensory or autonomic ganglia where it can later reactivate. Recurrent
HSV occurs in approximately 60% of those infected with type 1 HSV and 90% in type 2 HSV. Proctitis is usually associated with anal intercourse and diagnostic suspicion should be raised in the presence of perianal vesicles or painful oral/anogenital ulceration.

PCR on rectal biopsy, or exudate from a lesion is the current ideal diagnostic modality for rectal HSV. Recommended treatment for acute infection is 5 days of either aciclovir 200 mg five times a day, aciclovir 400 mg three times a day, valaciclovir 500 mg twice a day, or famciclovir 125 mg twice a day. For recurrent HSV, aciclovir may be given four times a day for up to 1 year; however, only 20% of patients will see a subsequent reduction in disease recurrence.

It should be appreciated that anogenital ulcers associated with both HSV and syphilis lead to a 1.5 to sevenfold increase in HIV transmission due to the associated mucosal barrier breach, and so HIV testing should be undertaken.

SYPHILIS
Caused by the spirochete Treponema pallidum, the incidence of syphilis both in men and women has steadily risen in recent years, especially so in MSM. Primary syphilis presents within 3 months of exposure (on average within 2–3 weeks), with a painless solitary ulcer (chancre, see figure 1) and regional lymphadenopathy that may affect the genitalia, mouth or rectum.

Figure 1 Solitary syphilitic chancre affecting (a) male and (b) female external genitalia. A chancre is the archetypal feature of primary syphilis. These ulcers are classically anogenital, solitary, indurated and painless; however, in atypical cases they may be multiple and painful, and can occur at extra-anogenital sites.
These ulcers are typically indurated with a clean base and discharge serous fluid. If unidentified, primary disease can progress to secondary syphilis typically in 6–12 weeks (but up to 2 years) later, in which bacteremia leads to multisystem disease that may include peripheral neuropathy, maculopapular rash (typically palmoplantar, see figure 2), hepatitis, glomerulonephritis, meningitis or anterior uveitis. Secondary syphilis can also manifest with oral ulceration (typically with a snail tract distribution), proctitis and condylomata lata, which are wart-like papules commonly perianal or genital in anatomical origin. Covered in a greyish exudate, condylomata lata are highly infectious. Tertiary syphilis, which may occur several years following primary or secondary disease, can have major neurological or cardiovascular sequelae. These include dementia, paresis, seizures, aortitis or aneurysms. Tertiary syphilis may also feature gumma, which are granulomatous nodules or ulcers of the gastrointestinal tract or buttocks.

Early infection up to 2 years after acquisition without any manifestations of primary or secondary stages is described as early latent syphilis. Primary, secondary and early latent stages of syphilis are infectious, whereas the later stages of tertiary syphilis are largely non-infectious. Emphasis should therefore be placed on diagnosing and treating primary, secondary and early latent syphilis promptly so as to avoid later complications.

A diagnosis of syphilis can be made by dark ground microscopy or PCR of ulcer exudate, condylomata

**Figure 2** Palmoplantar rash in secondary syphilis. The skin eruption associated with secondary syphilis characteristically has a palmoplantar distribution, is pink or dark red and not pruritic.
lata exudate or rectal biopsies. It may be 12 weeks from infection until antibodies become detectable within serum, and so a repeat blood sample 3 months following last sexual risk may be required. When a diagnosis is suspected or confirmed, GUM or infectious disease specialists should be consulted. Contact tracing and screening is necessary, as between 40–60% of contactable sexual partners may be infected.6

First-line treatment of primary and secondary syphilis is ideally with intramuscular benzyl benzathine penicillin 2.4 million units once. This form of penicillin is slowly hydrolysed to benzylpenicillin giving sustained release, and is advantageous as it ensures bioavailability and can be supervised. Alternatively, intramuscular procaine penicillin 600 000 units a day for 10–14 days can be given. Second-line therapy is with doxycycline 100 mg twice a day for 14 days. For tertiary syphilis prolonged courses of the above therapies may be required.

OTHER SEXUALLY TRANSMITTED PATHOGENS THAT MAY CAUSE PROCTITIS

*Giardia lamblia* (giardiasis) and *Entamoeba histolytica* (amoebiasis) may also be inoculated by sexual contact.3 7 Spread by the faecal oral route, sexual transmission is most commonly seen in MSM.

**Giardiasis**

In giardiasis, protozoa adhere and replicate on the brush border of the duodenum and jejunum, feeding on the mucous secretions of the intestine. In some cases proctitis is evident. Classically patients will experience foul-smelling steatorrhoea around 2–3 weeks following infection. Diagnosis is by direct microscopy of faeces that may reveal trophozoites (the motile active feeding stage of the protozoan life cycle) in liquid faeces. Oocysts may be seen in either liquid or solid faeces; however, they may be excreted in a cyclical manner, and so repeated stool tests or in some cases duodenal biopsy or aspirate may be required to confirm the diagnosis. Faecal antigen detection kits may also aid diagnosis. Treatment of giardiasis is with metronidazole 400 mg three times a day for 5 days.

**Amoebiasis**

Diarrhoea caused by amoebiasis ensues 2–4 weeks following the ingestion of cysts, when trophozoites breach the mucosa causing an inflammatory infiltrate and subsequent proctocolitis. Diarrhoea, which can be bloody, may persist for several weeks. Diagnosis of *E histolytica* trophozoites or cysts is usually possible on microscopic examination of stool specimens. Treatment is with metronidazole 800 mg three times a day or tinidazole 2 g once a day for 5–8 days, coupled with diloxanide furoate 500 mg three times a day for 10 days to optimise eradication. Stool samples should be analysed at monthly intervals for 3 months following therapy as a test of cure, and further treatment should be provided if persistent amoebiasis is identified.

**IMPORTANT NON-INFECTIOUS DIFFERENTIAL DIAGNOSES OF STI-INDUCED PROCTITIS**

While certain genital, oral or systemic features may suggest an STI cause of proctitis, it is important to be aware that there are other less commonly encountered non-infectious causes of proctitis that may display similar characteristics. These include Behçet’s syndrome and solitary rectal ulcer syndrome (SRUS).

**Behçet’s syndrome**

Classically presenting with orogenital ulceration due to an underlying vasculitis, Behçet’s syndrome can also affect any part of the gastrointestinal tract.8 It may present with perianal ulceration, fistulation, segmental colitis and abdominal pain. Extra-intestinal manifestations including arthritis, anterior uveitis and erythema nodosum may lead to a misdiagnosis of Crohn’s disease. This is further compounded by the possibility of granulomata being found on biopsy. The prevalence of Behçet’s syndrome is greatest in the middle east, far east and the Mediterranean basin and is highest in Turkey at 8–42 per 1000 people. Within Behçet’s populations the prevalence of gastrointestinal involvement varies, being highest at approximately 30% in Japan. Thrombophlebitis of the legs is frequently observed and may be a subtle differentiating feature between IBD and Behçet’s syndrome. Endoscopically ulcers may appear well demarcated and ‘punched out’, sometimes without surrounding colitis. Histological examination of intestinal biopsies may reveal a lymphocytic infiltration, classically with vasculitis of small vessels; however, histology may be indistinguishable from IBD. A diagnosis of Behçet’s syndrome is consequently made clinically and is dependent on the presence of recurrent oral ulceration plus two of recurrent genital ulceration, eye lesions (uveitis or retinal vasculitis), skin lesions (erythema nodosum, pseudofolliculitis, papulopustular lesions, or acneform nodules in post-adolescent patients), or a positive pathergy test at 24–48 h (a sterile skin prick test that may lead to pustule or nodule formation; however, this test is often negative).9 Treatment options for intestinal manifestations of Behçet’s syndrome include 5-aminosalicylic acid, sulfasalazine, or azathioprine. Corticosteroids may be beneficial in some patients.

**Solitary rectal ulcer syndrome**

Commonly, SRUS presents with rectal bleeding, the passage of mucous and regularly a sensation of incomplete evacuation.10 The condition is often associated with rectal prolapse. Despite nomenclature, SRUS may present with erythema of the rectal mucosa, polypoid inflammation or multiple rather than single ulcers. Consequently, a misdiagnosis of IBD or malignancy may be made. Biopsy is therefore essential to exclude rectal adenocarcinoma, and histological features of thickened mucosa and smooth muscle...
extension from the muscularis into the lamina propria are characteristic of SRUS. In comparison to IBD, an inflammatory infiltrate is not a prominent finding on histology. Diagnosis is often possible on the basis of history and endoscopic examination; however, differentiating proctography and ultrasonography can be useful aids to diagnosis. Common findings on deflecting proctography include internal or external rectal prolapse, often with incomplete rectal evacuation. Endoanal ultrasound classically reveals a thickened internal anal sphincter, and may show contraction or failure of relaxation of the puborectalis muscle on straining. Treatment options have variable results and must be considered on an individual basis. These include biofeedback therapy to modify defecation behaviour, and surgical intervention including abdominal rectopexy.

FURTHER CONSIDERATIONS WHEN MANAGING PROCTITIS CAUSED BY A SEXUALLY TRANSMITTED PATHOGEN

Patients diagnosed in the gastroenterology clinic with an STI should be seen by an expert in sexual health and associated infections, when clear information regarding their diagnosis should be provided to patients and their sexual contacts. Partner notification and screening should be undertaken (partners in preceding 3 months for primary syphilis, chlamydia, LGV, or rectal gonorrhoea, and 2 years for secondary or latent syphilis), and this may help to identify sexual networks with a high risk of future transmission. Empirical treatment for partners may be recommended until negative results of investigations are available. With respect to HSV, patients should be given advice on transmission risks and sharing information with partners. Co-infection with other sexually transmitted pathogens is common and so full sexual health screening including HIV, hepatitis B and C is advisable.

CONCLUSION

When evaluating a patient with either new-onset disease, proctitis that has not responded to standard treatments for Crohn’s disease or ulcerative colitis, or in the presence of atypical clinical or laboratory features, there are several differential diagnoses outlined by this paper that must be considered. Box 2 describes common or key discriminating features of these conditions with respect to Crohn’s disease and ulcerative colitis. Box 3 outlines risk factors for STIs that should be considered by clinicians, and box 4 advises on taking a sexual history in the gastroenterology clinic. Sexual health experts should be consulted in cases of confirmed or suspected STI, when further screening for co-infection including HIV, hepatitis B and C should then be undertaken, along with tests of cure and partner identification as appropriate.

Box 2 Common or key discriminating features from Crohn’s disease or ulcerative colitis

- Gonorrhoea
  - Purulent urethral discharge
  - Pharyngeal infection
  - Gram-negative diplococci on Gram stain of anogenital swabs
  - Chlamydia co-infection common
- Lymphogranuloma venereum
  - Mucopurulent anal, urethral or vaginal discharge
  - Painful inguinal or femoral lymphadenopathy possibly with associated abscess formation
  - Low-grade fever and pyrexia
  - C trachomatis biovar L1, L2 or L3 identification on nucleic acid amplification test and genotyping
- Chlamydia
  - Proctitis symptoms usually mild (often asymptomatic)
  - Neutrophils may be seen on microscopy of anal discharge
- Gonorrhoea co-infection common
- Herpes simplex virus
  - Malaise, headaches and myalgia
  - Perianal vesicles or ulcers
  - Painful genital ulceration
  - HSV type 1 or 2 identification on PCR
- Syphilis
  - Painless rectal or orogenital chancre (primary disease)
  - Snail tract oral ulceration
  - Condylomata lata
  - Associated neurological, cognitive and vascular co-morbidities (secondary and tertiary disease)
- Gastrointestinal or gluteal gummatous ulceration or nodules
- Behcet’s syndrome
  - Punched-out oral ulceration
  - Proctocolonic ulcers may not have surrounding proctocolitis.
  - Lower limb thrombophlebitis
  - Genital ulceration
  - Eye and skin lesions common
  - Positive pathergy test
- Solitary rectal ulcer syndrome
  - Rectal prolapse
  - Smooth muscle extension from muscularis into lamina propria and relative absence of inflammatory infiltrate on histology

BEST OF FIVE QUESTIONS

Question 1

A 23-year-old man presented with an 8-week history of bloody diarrhoea, severe anorectal pain and low-grade pyrexia. On further questioning he also complained of malaise, myalgia and arthralgia. He admitted to unprotected receptive anal sexual intercourse with two male partners in the preceding 6 months. Perianal and rectal examination revealed two fluctuant, tender areas of induration adjacent to the anal verge suggestive of abscesses. An urgent flexible sigmoidoscopy revealed inflamed, friable rectal mucosa.

Box 3 Risk factors associated with sexually transmitted infections

- Younger age (less than 25 years at highest risk)
- People from or who have visited countries with higher rates of STI
- Men who have sex with men
- Frequent partner change or multiple concurrent partners
- Early onset sexual activity
- Previous STI or previous contact with STI
- Alcohol or substance misuse
with several large ulcers and spontaneous bleeding. Rectal swabs sent for NAAT and genotyping revealed the presence of *C trachomatis* genotype L1.

Which of the following is the most appropriate treatment regimen:

A—Doxycycline 100 mg twice a day for 7 days
B—Erythromycin 250 mg four times a day for 21 days
C—Ofloxacin 400 mg a day for 7 days
D—Erythromycin 500 mg twice a day for 7 days
E—Doxycycline 100 mg twice a day for 21 days

**Question 2**

A 32-year-old man presents with a 6-week history of diarrhoea, anorectal pain and maculopapular rash affecting the trunk, hands and feet. Two years previously he had been investigated for possible Crohn’s disease after presenting with several perianal and anal verge ulcers. These had resolved spontaneously and no formal diagnosis had been made. On further questioning he admitted to a 4-week history of perianal swelling and several oral ulcers with a snail track distribution on inspection. Perianal inspection is demonstrated in figure 3.

What is the most likely causative organism:

A—HSV
B—*T pallidum*
C—*N gonorrhoea*
D—*C trachomatis*
E—Human papilloma virus

**Question 3**

A 40-year-old male patient of Turkish origin presented to ophthalmology as an emergency with acute painless reduced visual acuity in both eyes. Further questioning revealed a several year history of intermittent diarrhoea, recurrent oral and penile ulceration, with orogenital scarring evident on examination. He also complained of painful red nodules on the extensor aspects of both forearms. One year previously he had been diagnosed with anterior uveitis requiring prolonged steroid use. Slit lamp retinal examination revealed multiple intraretinal haemorrhages, soft exudates and macular oedema in both eyes.

What is the most likely diagnosis:

A—Crohn’s disease
B—Sarcoidosis
C—Behçet’s syndrome
D—Tuberculosis
E—Multiple sclerosis

---

**Box 4 Components of and tips for taking a sexual history in the gastrointestinal clinic**

- **Components**
  - Symptoms: Duration, association with genital or bladder symptoms, presence and colour of discharge
  - Partners: Last sexual intercourse, partner gender, establish number of partners within preceding 3–6 months, partner symptoms, type of sexual intercourse (oral, vaginal or anal)
  - Contraception: Specifically the use of condoms
  - History of STI: Previous diagnoses and treatment of STI or partner diagnoses/treatment
  - Foreign travel: Travel to areas of high incidence
  - Social history: Including alcohol and drug misuse
  - For women: Last menstrual period
- **Tips**
  - Speaking to the patient alone may allow them to speak more openly about their symptoms and allow you to ask more detailed questions, as can utilising a sexual history proforma, used in many GUM clinics
  - Seek permission and explain why you are asking personal questions
  - Only ask what you need to know, avoid needlessly intrusive questions
Question 4
A 32-year-old woman presented to the endoscopy department for flexible sigmoidoscopy with a 1-month history of diarrhoea and abdominal pain. Two months previously she had been treated in primary care for chlamydia infection following a positive urine NAAT. Symptoms of dysuria and urethral discharge had continued despite 7 days doxycycline 100 mg twice a day. Endoscopy revealed mildly erythematous mucosa and loss of normal vascular pattern in the rectum associated with a purulent discharge. Anal and urethral swabs were obtained and the resultant Gram stain is shown in figure 4.

What is the most likely causative organism:
A—C trachomatis
B—HSV
C—Human papilloma virus
D—T pallidum
E—N gonorrhoea

Answer 1: E
The symptoms described and positive testing for C trachomatis serovar L1 are diagnostic of LGV. While a 7-day course of doxycycline 100 mg twice a day, ofloxacin 400 mg a day or erythromycin 500 mg twice a day would be appropriate to treat uncomplicated serovar D–K C trachomatis, LGV caused by invasive serovar L1, 2, or 3 requires 21 days of therapy, and while erythromycin would be appropriate, a higher dose of 500 mg four times a day would be required. The correct answer is therefore doxycycline 100 mg twice a day for 21 days.

Answer 2: B
The depicted flat-topped, papillomatous perianal lesions are typical of condylomata lata, a feature of secondary syphilis caused by T pallidum. The described oral ulceration and macular rash with a palmoplantar distribution are also typical of secondary syphilis. The previous perianal ulcers are likely to have represented multiple primary syphilitic chancres, as although these are classically singular, multiple lesions may be seen.

Answer 3: C
The ocular findings are consistent with retinal vasculitis that can be confirmed by fluorescein angiography. The painful nodules on his forearms are suggestive of erythema nodosum, and these diagnoses associated with previous anterior uveitis, recurrent orogenital ulceration and gastrointestinal symptoms are consistent with Behçet’s syndrome. The highest prevalence of Behçet’s syndrome is in Turkey. Tuberculosis, sarcoidosis and Crohn’s disease are among the differential diagnoses; however, recurrent genital ulceration would be uncommon and is more typically a finding of Behçet’s syndrome. Orogenital ulceration is not a feature of multiple sclerosis.
Answer 4: E

The Gram stain reveals numerous neutrophils, many with intracellular Gram-negative diplococci (arrows in figure 5) consistent with *N gonorrhoea* infection. Co-infection with gonorrhoea is commonly associated with chlamydia, and gonorrhoea would not have responded to the previous course of doxycycline, hence the patient’s ongoing symptoms. Rectal infection with gonorrhoea can occur due to the transmucosal spread of infected urethral discharge. Appropriate therapy for gonorrhoea proctitis includes ceftriaxone 500 mg intramuscularly once, plus oral azithromycin 1 g once.

Contributors CAL devised the concept for the manuscript, which was subsequently developed by CAL and EIML. Initial drafting was undertaken by CAL, all authors contributed to subsequent drafts. KNS supplied the colour images used in this paper.

Patient consent Obtained.

Funding None.

Competing interests None.

Provenance and peer review Not commissioned; internally peer reviewed.

REFERENCES


